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1. Introduction 
Myasthenia gravis (MG) is a heterogeneous disorder with a protean, clinical, pathologic, 
and immunobiological picture(Beekman, Kuks, and Oosterhuis 1997, 244:112-118) 
Myasthenia gravis (MG) is the best studied and understood autoimmune disease. The 
autoimmune origin of the disease was suggested for the first time by Simpson (Simpson 
1982, 226:1045-1050), but Almon and colleagues(Almon and Appel 1976, 274:235-243) were 
the first to demonstrate circulating antibodies to acetylcholine receptor (AchR) sites of the 
neuromuscular junction. Elevated antibody levels are found in approximately 90% of 
patients and are roughly correlated with the clinical severity of the disease(Beekman, Kuks, 
and Oosterhuis 1997, 244:112-118). As Lennon (Lennon, Lindstrom, and Seybold 1976, 
274:283-299) showed, the thymus is evidently implicated in the production not only of these 
end-plate antibodies but also to striated muscle antibodies through some aberration in its 
normal function. 
In most cases, the target of the autoimmune attack is the nicotinic acetylcholine receptor 
(AChR) located in the postsynaptic muscle endplate membrane. AChR antibodies produce 
deficient neuromuscular transmission by three different mechanisms: 
• they bind to the AChR and alter function; 
• they promote endocytosis and accelerate the degradation rate of AchR 
• antibodies activate complement leading to destruction of the postsynaptic 
surface(Hughes, Moro De Casillas, and Kaminski 2004, 24:21-30).  
Other neuromuscular junction antigens, distinct from AChR, also play a role in autoimmune 
attack of patients with MG. Up to 20% of patients with generalized MG are seronegative for 
AChR antibodies with 30% of these patients having autoantibodies directed against  a distinct 
endplate membrane intrinsic protein, muscle-specific receptor tyrosine kinase (MuSK) (Evoli 
et al. 2003, 126:2304-2311). Some MuSK antibodies compromise AChR channel function, but 
specific pathogenic mechanisms have not been defined. One would predict that MuSK 
antibodies compromise neuromuscular transmission by affecting AChR clustering at the 
neuromuscular jonction. Patients who have late onset non-tumoral MG may also have tintin 
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(an intracellular muscle protein) and ryanodine receptor antibodies, the presence of these 
antibodies being associated with a worse prognosis (Romi, Gilhus, and Aarli 2006, 183:24-25). 
The thymus plays a key role in tolerance induction to self-antigens and in responsiveness of 
lymphocytes to foreign antigens.  Several findings indicate that the thymus is involved in 
MG pathogenesis: 
• Pathological changes, like lymphoid follicular hyperplasia or thymomas, are frequent in 
patients with MG. 
•  MG thymic tissue contains abnormally elevated amounts of mature T cells, most of 
them  AChR-reactive T cells(Sommer et al. 1990, 28:312-319;Sommer, Tackenberg, and 
Hohlfeld 2008, 91:169-212).  
• myasthenic thymic tissue fragments  transplanted to severe combined 
immunodeficiency mice produce human antibodies, which bind to the 
AChR(Schonbeck et al. 1992, 90:245-250).  
Most myasthenic thymuses contain B cells capable of producing AchR antibodies, 
particularly those hyperplastic thymuses with germinal centers(Leite et al. 2007, 171:893-
905). Normal and myasthenic human thymuses express gene transcripts and epitopes of all 
AchR As subunits(Navaneetham et al. 2001, 24:203-210). 
The availability of AChR  in thymus may play a role in pathogenesis of MG. It is considered 
that the AChR expressed on thymic myoid cells is the original auto-sensitizing antigen, and 
the thymic changes in MG are primary events in the autoimmune pathogenesis of the 
disease(Leite, Jones, Strobel, Marx, Gold, Niks, Verschuuren, Berrih-Aknin, Scaravilli, 
Canelhas, Morgan, Vincent, and Willcox 2007, 171:893-905). It is possible that the myoid cells 
to be altered by viral illness involving the thymus and the proximity to antigen presenting 
cells and helper T-cells to facilitate the abnormal immunologic response(Drachman 1994, 
330:1797-1810). 
Patients with MG have frequently other immune-mediated diseases like rheumatoid arthritis, 
lupus, Graves’ disease, tyroiditis and a family history of autoimmune disorders. That imposed 
the study of the genetic factor implication in MG. HLA types like HLA-B8, DRw3, Dqw2 have 
been associated with AChR antibody positive MG and haplotypes DR14 and DQ5 with MuSK 
antibody positive MG(Carlsson et al. 1990, 31:285-290;Niks et al. 2006, 66:1772-1774). 
Since the first case reported by Schumacher and Roth in 1913 (Keesey 2004, 24:5-16), the role 
of thymectomy in MG treatment has been well established. The main study demonstrating  
the benefit of thymectomy in MG was that of Buckingham and associates(Buckingham et al. 
1976, 184:453-458), who compared the clinical course of patients after thymectomy with a 
computer-matched cohort receiving medical therapy. The best assessment of potential 
benefits of thymectomy in modern era comes from a review of 21 controlled but non-
randomized studies(Gronseth and Barohn 2000, 55:7-15) showing that patients undergoing 
thymectomy were twice as likely to achieve medication-free remissions. 
2. Indication (thymectomy in the multimodal treatment of MG) 
The major issues for a surgeon who has an interest in thymectomy are related to patient 
selection and surgical technique. Regarding patient selection, decision should be taken in 
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cooperation with the neurologist that supervised the treatment. Coordinated and strong 
multidisciplinary collaboration among neurologists, surgeons and anaesthesiologists is 
mandatory in making appropriate decisions regarding patient selection, therapeutic options 
and the timing of surgery. 
There is a current consensus that a patient with generalized non-tumoral MG who is 
between puberty and 60 years of age should undergo surgery, but the optimal approach is 
still under debate(Toyka KV and Gold R 2007, 158:309-321). Surgery for patients older than 
60 years is controversial. In patients with ocular myasthenia the benefit is uncertain (Bulkley 
et al. 1997, 226:324-334;Guillermo et al. 2004, 109:217-221) 
Nowadays surgical procedures for thymectomy in non-tumoral MG comprise transternal, 
transthoracic, transcervical, subxifoidian or thoracoscopic thymectomy. The primary goal of 
every technique, of every surgeon doing thymectomy is “to remove as much thymus and 
ectopic thymus as possible”(Rubin 2006, 82:1007-1008). An optimal approach should 
combine least invasiveness and maximal radicality. 
This is related with Jaretski’s (Jaretzki, Steinglass, and Sonett 2004, 24:49-62;Jaretzki, III and 
Wolff 1988, 96:711-716) now classic point of view in relation to thymus anatomy: that the 
main body of the gland, incapsulated  consisting in a right and a left lobe that join at their 
central portion just caudal to the left innominate vein, is accompanied with small 
extracapsular foci of thymic tissue distributed widely in mediastinal and cervical adipose 
tissue. This is the reason why the surgical technique consists in rigorous emptying of the 
anterior mediastinum from diaphragm to the cervical area, between the phrenic nerves, of 
all thymus and fatty tisuue. Advantages of thoracoscopic thymectomy besides minimizing 
the trauma and undoubted cosmetic advantages consist in the exceptional intraoperative 
overview (the new high definition cameras make these images even more accurate) that 
make the procedure safer, and diminishing the risk of injury of fine structures not related 
with the procedure. 
The diagnosis of myasthenia gravis is based on the patient’s history, physical examination, 
positive response to anticholinesterase agents and electrophysiology studies. Preoperative 
diagnostic tests should include spirometry and a CT scan. The immunologic profile with 
AchR antibodies assay and anti-MuSK antibody should be performed on all patients. 
Thymectomy should be performed when MG is in a stable condition; there is no indication 
for “emergency operation”. Al the patients should be well prepared for the intervention. In 
our experience patients were considered suitable for a surgical procedure only when 
evidence showed good treatment tolerance and a decrease of the quantitative myasthenia 
gravis score (Myastenia Gravis Foundation of America (MGFA) recommendations for 
clinical research standards (Jaretzki, III et al. 2000, 70:327-334)) to at least 10 points. 
Unilaterally extended thoracoscopic thymectomy is performed with the patient under 
general anesthesia with double-lumen tube placement and lying in a 15-30° off-centre 
position (fig1). 
Choice of the side is matter of training, mentoring, safe complete removal of the thymus and 
peri-thymic fatty tissue from diaphragm to cervical area being the main goal. A versatile 
thoracic surgeon should be able to approach the thymus by a variety of methods and if a left 
side approach is not possible due to previous thoracotomy for example, a right side 
approach should be performed with the same dexterity, safety and preciseness.   
www.intechopen.com
 A Look into Myasthenia Gravis 
 
80
3. Left side approach or right side approach 
Three or four trocars are inserted into the left hemithorax. The operator stays on the left side 
of the patient in a caudal position to the cameraman, but these positions are not fixed and 
any improvement in better ergonomics or superior visualization should be taking into 
account. The monitor is on the right side of the patient. The first trocar (10–12 mm) is placed 




Fig. 1. Patient and trocar positioning 
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Pleural cavity exploration is facilitated by the selective right bronchus intubation and by 





Fig. 2. CO2 insufflations at a maximum of 10 mmHg pressure enlarge the anterior 
mediastinum space 
The second and third trocars (10–12 and 5–7 mm or 10-12mm, respectively) are placed 
through the third inter-costal space on the anterior axilary line and through the fourth or 
fifth inter-costal spaces on the mid-clavicle line. For females the incision should be done 
keeping in mind the important cosmetic problem of the peri –mammary scars. 
After a careful pleural cavity exploration we spot the anterior mediastinum. The capnotorax 
helps us also in the dissection. In order to have this support we need to start all the 
operations with incision of the mediastinal pleura along the two important landmarks of 
thymectomy: the phrenic nerve and the internal thoracic artery (fig3), allowing the gas 
dissection to help us.  
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The incision of the mediastinal pleura and the dissection of the thymus begin anterior to the 
left phrenic nerve and continue into the entire thymus compartment. The use of the 
ultrascision scalpel (Harmonic Scalpel Ultrascision; Ethicon Endo-Surgery) facilitates the 
dissection, decreases the time of the intervention, and avoids the risks of the 
electrocoagulation in this area. The cranial limit of the dissection, at the level of the 
mediastinal pleura, is the internal thoracic artery. The operation continues with dissection of 











Fig. 3. Landmarks of the anterior mediastinum in thymectomy (right side approach) 
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Fig. 4. Dissection of the left inferior thymus horn – beginning of the intervention 
The dissection of the thymic tissue together with pericardial fat goes cephalad on the 
pericardial plane (fig5) overtaking the median line, to the right of the thymus gland. The 
contra-laterally mediastinal pleura is opened and the inferior right thymic horn and 
pericardial fatty tissue is dissected in the same manner (fig6). We continue to dissect 
anterior, retrosternal, the mediastinal pleura being open on the right side till the right 
mammary pedicle. The posterior dissection continues similar, the pericardium, the aortic 
arch, the left brachiocephalic vein, and the superior vena cava are visualized and cleaned of 
all fat tissue or thymus. The most difficult area to dissect is in the aortopulmonary window 
(fig 7) and the  aortocaval groove (fig 8). At the superior pole, the dissection is performed in 
the anterior carotidal plane to the internal thoracic artery level. The left superior horn or 
some time both upper horns may occasionally pass behind, instead of in front of the 
brahiocephalic vein (fig 9). This anatomical variety is more difficult to be solved by 
thoracoscopic approach. We have to be aware of the vagus nerve ant left recurrent laryngeal 
nerve that goes close and dissect carefully inferior and posterior to the brahiocephalic vein 
and then superior, to free the cervical parts of the upper horns. Afterwards traction of the 
upper horns caudally permits the dissection of them behind the brahiocephalic vein, in 
order to visualize an eventual posterior thymus vein. 
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Fig. 5. Dissection in the pre-pericardial plane 
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Fig. 6. Dissection of the contra-laterally inferior horn (left side approach) 
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Fig. 7. Dissection of the aortopulmonary window 
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Fig. 8. Dissection of the aorto-caval groove 
 
Fig. 9. Posterior upper right thymus horn dissection (right side approach) 
The thymectomy ends with the identification of the superior part of the gland, the thyroid-
thymic ligament section, and freeing of the superior horns from the surrounding tissue. 
After dissecting the surrounding fascia and cutting the vessels that goes caudally from 
cervix, upper horns can be mobilized caudally by applying gentle traction (fig 10). Cervical 
skin transillumination is the indication that the cervical limit of the dissection has been 
reached. During the operation, we can visualize the superior, lateral, or medial arterial 
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thymic pedicles. They are clipped and cut or ultrasonically coagulated (fig 11). Dissection of 
the thymic veins is very important. The veins are very short and enter directly into the left 
brachiocephalic vein. Tearing out such a pedicle may cause a hemorrhage, which is very 
difficult to correct thoracoscopically. Visualization of the right phrenic nerve is necessary to 
complete the dissection of thymus and fatty tissue (fig 12). 
 
 Fig. 10. Dissection of the upper left horn 
 
Fig. 11. Clipping the thymus vein 
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Fig 12. Visualization of the right phrenic nerve (left side approach)  
We sometimes used a needle-scope camera that was inserted through the Veress needle in 
the contra lateral thorax to control the complete dissection (fig 13). 
Thymus extraction is quite easily done by enlarging the hole of one of the trocar ports and 
bagging the piece before extracting it (fig 14). We prefer to introduce the bag at the 
beginning of the intervention, this way any small piece of thymus or fatty tissue could be 
bagged during dissection.  
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Fig. 13. Control of the complete dissection with a needle-scope camera that was inserted 
through the Veress needle in the contra lateral thorax  
 
Fig. 14. Extractic the specimen in self-made bag  
The operation ends with the thymic cavity inspection, which can detect possible remnant 
tissue (fig 15). Finally, we wash the cavity with warm saline. At the end of the operation one 
or two drains can be placed in the pleural cavity through the inferior trocar ports. 
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Thoracoscopic thymectomy through the right side is performed in the same manner, the 
most difficult part of this approach being the aortopulmonary window(Ruckert et al. 2000, 
18:735-736) and left inferior horn. 
 
Fig 15. Landmarks of the anterior mediastinum at the end of thymectomy (right side 
approach) 
Yim and colleagues(Yim 1997, 64:584-585) favor the right thoracoscopic approach because: 
1. identification of the vena cava is a landmark for easier dissection of innominate vein,  
2.  the confluence of the innominate veins is easier to dissect by using a right approach,  
3.  ergonomically, it is easier for right-hand surgeons to dissect the thymus from inferior 
horns to upper horns with a right approach.  
To this we would add that the right approach allows a better view in the cervical area. 
Irrespective of the patient’s anatomic characteristics, every effort is made to perform a full 
removal of the thymic tissue by clearing the innominate vein and anterior pericardium from 
all mediastinal fat. We believe a left-side approach facilitates the procedure because most of 
the mediastinal fat is located on the left side of the anterior mediastinum. The use of a 30° 
endoscope (Karl Storz-Endoscopy) provides significant help. Although we share the opinion 
of Mineo and colleagues(Mineo, Pompeo, and Ambrogi 1997, 114:516-517) that thymectomy 
can be performed by either a left-side or a right-side approach, we believe the left-side 
approach has some advantages. In our experience, the dissection maneuvers are safer when 
performed on the left side because the right phrenic nerve is situated outside the surgical 
field, thus reducing the risk of an incidental lesion. It is also easier to perform a dissection of 
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the right side of the thymus by a left approach than a dissection of the left side of the 
thymus by right approach, especially for the aortopulmonary window. 
4. Personal results 
Since April 1999, a thoracoscopic approach has been used in all patients admitted in the 
Department of General Surgery and Liver Transplantation of Fundeni Clinical Institute with 
either nonthymomatous myasthenia gravis or stage I and IIa Masaoka thymomas. There 
have been 300 patients with  nontumoral myasthenia gravis (NTMG) that have suffered an 
extended thoracoscopic thymectomy in our center between April 1998 and April 2011. 
We considered that favourable outcomes requires highly coordinated teamwork involving a 
strong collaboration between neurologists, surgeons, and anesthesiologists in making 
appropriate decisions on selection of patients, therapeutic options, and timing of surgery. All 
of the patients received specific treatment for at least 3 months before surgery in the 
Department of Neurology of our institute. Patients were considered suitable for a surgical 
procedure only when evidence showed good treatment tolerance and a stable quantitative 
myasthenia gravis (QMG) score of at least 10 points. We did not operate patients with pure 
ocular myasthenia gravis because we considered that the indication for thymectomy in ocular 
myasthenia gravis remained controversial. We did not operate patients with age over 60 years. 
Treatment, morbidity, mortality, and postinterventional status at follow-up were also assessed 
according to the MGFA Recommendations for Clinical Research Standards, QMG scores being 
the most valuable tool in quantitative evaluation of clinical improvement or remission 
analysis. CSR was used as the end point for the evaluation of the efficacy and prognostic 
factors. Patients were considered to be in complete stable remission status if they exhibited no 
symptoms of MG for at least one year and had received no therapy for MG during that time. 
A left thoracoscopic approach was used for 29% of the patients and a right thoracoscopic 
approach for 71% of the patients. Decision to use the right-side or left-side approach was 
considered in relation with the CT aspect of each patient’s thymus. Extensive dissection in 
the region of the thyroid and lateral neck, through a separate collar incision, was not 
routinely performed. The low probability of finding aberrant thymic remnants in these 
locations did not justify this approach as a standard procedure. Minicervicotomies were 
performed on 7 patients, due to cervical extensions of the thymus. There were no 
conversions to open thymectomy. The mean operative time was of 80+/- 45 min. There was 
zero mortality and morbidity was observed in 14 patients (4.66%): 10 patients previously 
reported(Tomulescu et al. 2006, 82:1003-1007) (severe postoperative myasthenia crisis in 1 
patient who needed mechanical ventilation for 5 days, 2 with contralateral pneumothorax 
after drain removal, 3 with hemothorax that required emergent reintervention, and 6 with 
prolonged pleural drainage) and 2 patients with postoperative pneumonia.  
The mean length of hospitalization was 2.1 days (range: 2-6 days).  
Evaluating the post-interventional status according to the MGFA recommendations for 
Clinical Research Standards complete stabile remission (CSR) have been obtained in 62% 
(186 patients), pharmacologic remission (PR) in 8% (24 patients), minimal manifestation 
(MM) in 15% (45 patients), non changed (N) in 10% (30 patients), worse (W) in 1% (3 
patients) and exacerbation (E) - patients who have fulfilled the criteria of CSR, PR, or MM 
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but subsequently developed clinical findings greater than permitted by these criteria - in 4% 
(12 patients). 
5. Conclusions 
Unilaterally extended thoracoscopic thymectomy is a technically demanding procedure that 
requires expertise in extended thymectomy and in advanced minimally invasive techniques. 
The right side, the left side or even bilateral approach should be chosen in relation with the 
method the surgeon is more comfortable and from which best results (morbidity, mortality, 
completeness of thymectomy) should be expected. 
The maximal thymectomy should remain the benchmark against which other thymectomy 
techniques are measured (whether or not it is the surgical technique of choice) (Jaretzki, III, 
Barohn, Ernstoff, Kaminski, Keesey, Penn, and Sanders 2000, 70:327-334;Jaretzki, III and 
Wolff 1988, 96:711-716; Sonett and Jaretzki, III 2008, 1132:315-328) but we consider that with 
no mortality, low morbidity, comparable CSR and PR, better cosmetic and pulmonary 
function-sparing effect, superior compliance from the patients and neurologists with a 
higher rate acceptance of surgical treatment, this minimally invasive approach could 
become the best first solution in the multimodal treatment of myasthenia gravis. 
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